neuroblastoma | pharmaphorum

Skip to main content

Friday 5 December 2025

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

neuroblastoma

News

lee_morley

EUSA Pharma looks to further in-licensing to build growth

Specialist company EUSA Pharma is looking for new medicines to develop after getting two cancer drugs recommended by European regulators this year.

News

European union flag against parliament in Brussels, Belgium

EUSA Pharma approval fills gap in neuroblastoma market

Company can move in after United Therapeutics withdrew its product Unituxin

News

Closeup of X-ray photography of human brain

Brain cancer drug too expensive, says NICE

Unituxin too costly for use in children, NICE says.

Editor's Picks

Latest Medicare pricing cuts promise $12bn in savings

NICE backs NHS use of Autolus' leukaemia CAR-T

£800m life sciences cluster opens in London

Sanofi's Paris HQ raided in tax fraud probe

Wearable alert system for epileptics set for European launch

News

Elderly woman at group exercise class

NHS use of digital cardiac rehab tools endorsed

Seven digital health technologies used to support people recovering from cardiovascular diseases have been recommended for use by the NHS.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company